Dámaris Priscila Intriago-Baldeón

Ms. Dámaris Priscila Intriago-Baldeón

Faculty of Health Sciences, Universidad Internacional SEK, Quito, Pichincha, Ecuador
orcid
Professor in Cell and Molecular Biology and Researcher in Mo...

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
SGSantiago Guerrero
Santiago Guerrero
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
ÁCÁngela León Cáceres
Ángela León Cáceres
NSNéstor W. Soria
Néstor W. Soria

15 June 2020 in Generics and Biosimilars Initiative Journal
Verified
Journal Article
Closed access
EOEsteban Ortiz-Prado
Esteban Ortiz-Prado
JPJorge Ponce-Zea
Jorge Ponce-Zea
JVJorge E Vasconez
Jorge E Vasconez
DCDiana Castillo
Diana Castillo
DCDiana C Checa-Jaramilloz
Diana C Checa-Jaramilloz
CGClaudio Galarza-Maldonado
Claudio Galarza-Maldonado
The number of approved biological medicines in the global pharmaceutical market has increased in recent decades. However, their high costs have also promoted the development of biosimilar medicines, following the expiry of the patent of the reference drug. Biosimilars are approved medicines of biological origin which have no statistically significant differences in terms of quality, safety and therapeutic efficacy in comparison with the reference biological. Drugs marketed as biomimics meanwhile are copies of monoclonal antibodies and fusion proteins that have not demonstrated bioequivalence to their reference biologicals. Across the world, regulations have been developed to ensure the safety and efficacy of biosimilar products, which can reduce public health expenditure and improve patient access to biological medicines. As a result, Latin America has begun to invest in the development of these drugs. The objective of this literature review is to describe the development of the biosimilar and biomimic market in Latin America.

1 June 2015 in Biochemical Systematics and Ecology
Verified
Journal Article
Closed access
JGJuan J. Guadalupe
Juan J. Guadalupe
BGBernardo Gutiérrez
Bernardo Gutiérrez
Dámaris Priscila Intriago-BaldeónDámaris Priscila Intriago-Baldeón
Dámaris Priscila Intriago-Baldeón
VAVenancio Arahana
Venancio Arahana
JTJosé Tobar
José Tobar
MTMaria de Lourdes Torres
Maria de Lourdes Torres

27 May 2016 in Stem Cell Investigation
Verified
Journal Article
Open access
PDF file
JYJay-Sze Yong
Jay-Sze Yong
Dámaris Priscila Intriago-BaldeónDámaris Priscila Intriago-Baldeón
Dámaris Priscila Intriago-Baldeón
Eric LamEric Lam
Eric Lam
FOXD3 controls pluripotency through modulating enhancer activity

Verified
Journal Article
Open access
PDF file
Dámaris Priscila Intriago-BaldeónDámaris Priscila Intriago-Baldeón
Dámaris Priscila Intriago-Baldeón
Eduarda Sofía PérezEduarda Sofía Pérez
Eduarda Sofía Pérez
MSMartina Isabella Armas Samaniego
Martina Isabella Armas Samaniego
VRVanessa Romero
Vanessa Romero
JPJuan Carlos Pozo Palacios
Juan Carlos Pozo Palacios
GOGabriele Davide Bigoni Ordóñez
Gabriele Davide Bigoni Ordóñez
Breast cancer is the most frequent gynecological malignancy and the main cause of cancer death in the female population worldwide. One of the most significant challenges in its clinical management is the molecular heterogeneity of malignant breast tumors, which is reflected in the current molecular classification of these entities. In each of these tumor molecular subtypes, distinct genetic alterations are involved, and several intracellular signaling pathways contribute to defining their biological identity and clinical response. This literature review summarized the main classic and emerging biomarkers in breast cancer, along with the therapies associated with them. There are several classic biomarkers associated with this disease, such as estrogen and progesterone receptors, the HER2 receptor, and the Ki-67 cell proliferation marker. Given the limitations of these biomarkers, new biomarkers have been identified, including the TP53 tumor suppressor gene, the EGFR, different types of RNAs, plus epigenetic and immunological biomarkers. The integration of classic and emerging biomarkers along with new therapeutic targets in the clinical practice has promoted a thorough understanding of the high molecular complexity of breast cancer and the development of precision medicine strategies which increase the chances of therapeutic success.

26 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
SGSantiago Guerrero
Santiago Guerrero
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
Dámaris Priscila Intriago-BaldeónDámaris Priscila Intriago-Baldeón
Dámaris Priscila Intriago-Baldeón
NSNéstor W. Soria
Néstor W. Soria
Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Over the last decades, several studies have shown that tumor-related genomic alterations predict tumor prognosis, drug response and toxicity. These observations have led to the development of a number of precision therapies based on individual genomic profiles. As part of these approaches, pharmacogenomics analyses genomic alterations that may predict an efficient therapeutic response. Studying these mutations as biomarkers for predicting drug response is of a great interest to improve precision medicine. Here we conduct a comprehensive review of the main pharmacogenomics biomarkers and genomic alterations affecting enzyme activity, transporter capacity, channels and receptors, and therefore the new advances in CRC precision medicine to select the best therapeutic strategy in populations worldwide, with a focus on Latin America.